

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
KW	A	3	9	9	4	9	7	4	11/30/76	Murakami et al	260	562	05/07/74
	B	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
	C	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
	D	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
	E	5	5	2	5	6	2	3	06/11/96	Spear et al	514	423	03/11/94
	F	5	6	0	2	1	1	0	02/11/97	Drumm et al	514	47	01/26/95
	G	5	6	5	4	2	7	6	08/05/97	Barrett et al	514	13	06/07/95
	H	5	6	6	8	1	1	0	09/16/97	Barrett et al	514	13	06/07/95
	I	5	6	7	4	8	6	0	10/07/97	Carling et al	514	171	10/03/94
	J	5	6	7	7	2	8	0	10/14/97	Barrett et al	514	14	06/07/95
	K	5	6	7	7	8	0	9	10/14/97	Kadlec	360	78.09	06/01/95
	L	5	6	8	3	9	8	3	11/04/97	Barrett et al	514	12	06/07/95
	M	5	6	9	1	3	3	6	11/25/97	Dorn et al	514	236.2	09/08/95
	N	5	7	3	3	5	2	6	03/31/98	Trevino et al	424	9.52	12/14/95
	O	5	7	5	0	5	4	9	05/12/98	Caldwell et al	514	364	10/15/96
	P	5	7	8	0	4	6	7	07/14/98	Dorn et al	514	236.2	08/08/97
	Q	5	7	9	5	5	6	4	08/18/98	Aberg et al	424	45	03/07/96
	R	5	8	7	4	4	8	1	02/23/99	Weers et al	514	761	06/07/95
	S	5	8	7	7	1	9	1	03/02/99	Caldwell et al	514	337	10/22/97
	T	5	9	2	9	0	9	4	07/27/99	Durette et al	514	340	10/22/97
	U	5	9	6	5	6	2	2	10/12/99	Senanayake	514	653	06/23/98
	V	5	9	7	2	9	1	9	10/26/99	Carling et al	514	171	10/07/97
	W	6	0	0	4	5	3	7	12/21/99	Blondino et al	424	45	12/18/98
he	X	6	0	4	0	3	4	4	03/21/00	Gao et al	514	554	05/21/98

EXAMINER

W. Widdows

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FEB 20 2002

TOH CENTER 1600/2900

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
EW	Y	6	0	4	1	7	7	7	03/28/00	Faithfull <i>et al</i>	128	200.24	12/01/95
	Z	6	0	6	8	8	3	3	05/30/00	Aberg <i>et al</i>	424	45	08/18/98
	AA	6	0	7	1	9	7	1	06/06/00	Senanayake	514	653	05/05/99
	AB	6	1	2	6	9	1	9	10/03/00	Stefely <i>et al</i>	424	45	02/07/97
	AC	6	1	3	6	6	0	3	10/24/00	Dean <i>et al</i>	435	375	03/26/99
	AD	6	1	5	0	4	1	8	11/21/00	Hochrainer <i>et al</i>	514	630	11/12/99
EW	AE	6	1	6	1	5	3	6	12/19/00	Redmon <i>et al</i>	128	200.14	10/07/98

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
EW	AF	2	3	0	5	0	9	2	02/02/73	Germany	—	—		
EW	AG	9	9	0	0	1	3	4	07/01/99	PCT	—	—		
EW	AH	9	9	3	6	0	9	5	22/07/99	PCT	—	—		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	AI	Bartow and Brogden, "An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," <i>Drugs</i> , 55(2):303-322 (1998)
	AJ	Campbell <i>et al</i> , "A comparison of the efficacy of long-acting B2-agonists: eformoterol via Turbuhaler(R) and salmeterol via pressurized metered dose inhaler or Accuhaler (R), in mild to moderate asthmatics," <i>Respiratory Medicine</i> , 93:236-244 (1999)
	AK	Dellamary <i>et al</i> , "Hollow Porous Particles in Metered Dose Inhalers," <i>Pharmaceutical Research</i> , 17(2):168-174 (2000)
	AL	Derwent# 000971705, WPI Acc. No. 1973-48969U/197335 citing German Patent Application No. DE 2305092 A, "Alpha-aminomethylbenzyl alcohol derivs. -prepd. by redn. of corresponding protected derivs."
EW	AM	Ekstrom <i>et al</i> , "Low-dose formoterol Turbuhaler(R) (Oxis(R)) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)," <i>Respiratory Medicine</i> , 92:1040-1045 (1998)

EXAMINER

K. Weddington

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614RECEIVED  
FEB 20 2002  
TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AN	Kaumann and Lemoine, "Direct labelling of myocardial B1-adrenoceptors; Comparison of binding affinity of 3H(-)-bisoprolol with its blocking potency," <i>Archives of Pharmacology</i> , <u>331</u> :27-39 (1985)
AO	Lecaillon <i>et al</i> , "Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer (TM)," <i>European Journal Clinical Pharmacology</i> , <u>55</u> :131-138 (1999)
AP	Lemoine <i>et al</i> , "Direct labelling of B2-adrenoceptors; Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551," <i>Archives of Pharmacology</i> , <u>331</u> :40-51 (1985)
AQ	Lotvall <i>et al</i> , "Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler," <i>Can Respir J</i> , <u>6</u> (5):412-416 (1999)
AR	Nielsen <i>et al</i> , "Flow-dependent effect of formoterol dry-powder inhaled from the Aeolizer (R)," <i>Eur Respir J</i> , <u>10</u> :2105-2109 (1997)
AS	Nightingale <i>et al</i> , "Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma," <i>Am J Respir Crit Care Med</i> , <u>159</u> :1786-1790 (1999)
AT	Nogrady, T., (editor), <i>Medicinal Chemistry: A Biochemical Approach</i> , Oxford University Press, New York, pgs. 388-392 (1985)
AU	Palmqvist <i>et al</i> , "Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency," <i>Eur Respir J</i> , <u>10</u> :2484-2489 (1997)
AV	Rico-Mendez <i>et al</i> , "Formoterol en polvo seco, dos veces al dia versus salbutamol aerosol, cuatro veces al dia, en pacientes con asma estable," <i>Revista Alergia Mexico</i> , <u>XLVI</u> (5):130-135 (1999)
AX	Ringdal <i>et al</i> , "Onset and duration of action of single doses of formoterol inhaled via Turbuhaler(R)," <i>Respiratory Medicine</i> , <u>92</u> :1017-1021 (1998)
AY	Schreurs <i>et al</i> , "A dose-response study with formoterol Turbuhaler(R) as maintenance therapy in asthmatic patients," <i>Eur Respir J</i> , <u>9</u> :1678-1683 (1996)
AZ	Seberova and Andersson, "Oxis(R) (formoterol given by Turbuhaler(R)) showed as rapid an onset of action as salbutamol given by a pMDI," <i>Respiratory Medicine</i> , <u>94</u> :607-611 (2000)
BA	Selroos <i>et al</i> , "Delivery Devices for Inhaled Asthma Medication," <i>Clin Immunother</i> , <u>6</u> :273-299 (1996)
BB	Tomiooka <i>et al</i> , "Anti-Allergic Activities of the B-Adrenoceptor Stimulant Formoterol (BD 40A)," <i>Arch Int Pharmacodyn</i> , <u>250</u> :279-292 (1981)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

TECH CENTER 600/2900

FEB 20 2002

RECEIVED

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Ce	BC	Totterman <i>et al.</i> , "Tolerability to high doses of formoterol and terbutaline via Turbuhaler(R) for 3 days in stable asthmatic patients," <i>Eur Respir J</i> , <u>12</u> :573-579 (1998)
ll	BD	Ullman <i>et al.</i> , "Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study," <i>Allergy</i> , <u>51</u> :745-748 (1996)

EXAMINER

40. Wadley

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#13  
Sheet 1 of 1  
**RECEIVED**  
AUG 2 9 2002  
TECH CENTER 1600/2000

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee et al.	
	FILING DATE June 22, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
NONE						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
NONE					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Kw		"Flovent", Glaxo Wellcome Inc., <u>Physicians' Desk Reference</u> , 54th ed., (2000), pp. 1186-1189
Kw	-	Warne, P.J., "The discovery and clinical development of RPR 106541: an airway-selective steroid for the treatment of asthma", <u>Emerging Drugs</u> , 5(2):231-239 (2000)

EXAMINER <u>W. Weddington</u>	DATE CONSIDERED <u>1-17-03</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Title: <b>BRONCHODILATING COMPOSITIONS AND METHODS</b>	

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

Sheet 1 of 7

#15  
RECEIVED  
DEC 02 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
ICG	3001	0	0	2	4	6	4	1	09/27/01	Yang	424	46	04/02/01
	3002	0	0	3	2	1	4	9	03/14/02	Kensey	514	1	04/24/01
	3003	0	0	6	1	8	3	5	05/23/02	Kensey	514	1	04/09/01
	3004	0	0	8	1	2	6	6	06/27/02	Woolfe <i>et al.</i>	424	46	08/14/01
	3005	0	0	9	9	0	1	3	07/25/02	Piccariello <i>et al.</i>	514	12	08/22/01
	3006	0	1	0	3	2	6	0	08/01/02	Clarke <i>et al.</i>	514	630	08/15/01
	3007	0	1	5	1	5	9	7	10/17/02	Banerjee <i>et al.</i>	514	629	07/22/01
	H	4	3	3	5	1	2	1	06/15/82	Phillipps <i>et al.</i>	424	241	02/13/81
	I	4	9	9	2	4	7	4	02/12/91	Skidmore <i>et al.</i>	514	653	08/23/89
	J	5	1	2	6	3	7	5	06/30/92	Skidmore <i>et al.</i>	514	651	11/29/90
	K	5	2	2	5	4	4	5	07/06/93	Skidmore <i>et al.</i>	514	651	02/19/92
	L	5	2	7	0	3	0	5	12/14/93	Palmer	514	171	09/03/91
	M	5	2	9	0	8	1	5	03/01/94	Johnson <i>et al.</i>	514	651	11/25/91
	N	5	8	7	4	0	6	3	02/23/99	Briggner <i>et al.</i>	424	45	02/26/96
	O	5	9	8	0	9	4	9	11/09/99	Trofast	424	489	01/09/98
	P	5	9	8	3	9	5	6	11/16/99	Trofast	141	1	01/09/98
	Q	6	0	3	0	6	0	4	02/29/00	Trofast	424	46	01/09/98
	R	6	2	8	7	5	4	0	09/11/01	Trofast	424	46	11/02/99
ICG	S	6	3	6	9	1	1	5	04/09/02	Ward	514	728	03/20/00

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
ICG	T	0	0	0	6	1	2	1	02/10/00	PCT	—	—		X*
ICG	U	0	0	0	7	5	6	7	02/17/00	PCT	—	—		X*
ICG	V	0	0	1	6	8	1	4	03/30/00	PCT	—	—		

EXAMINER

W. Widdows

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
100	W	0	0	2	8	9	7	9	05/25/00	PCT	—	—		X*
	X	0	0	3	0	6	1	2	06/02/00	PCT	—	—		
	Y	0	0	3	0	6	1	3	06/02/00	PCT	—	—		
	Z	0	0	3	3	8	9	2	06/15/00	PCT	—	—		
	AA	0	0	4	7	2	0	0	08/17/00	PCT	—	—		
	AB	0	0	4	8	5	8	7	08/24/00	PCT	—	—		
	AC	0	0	5	1	5	9	1	08/08/00	PCT	—	—		
	AD	0	0	5	3	1	8	7	09/14/00	PCT	—	—		
	AE	0	0	5	3	1	8	8	09/14/00	PCT	—	—		
	AF	0	1	2	7	1	0	7	04/19/01	PCT	—	—		
	AG	0	1	2	2	9	5	6	04/05/01	PCT	—	—		X*
	AH	0	1	3	2	1	6	3	05/10/01	PCT	—	—		
	AI	0	1	3	9	7	4	5	06/07/01	PCT	—	—		
	AJ	0	1	5	4	6	6	4	08/02/01	PCT	—	—		
	AK	0	1	7	0	1	9	8	09/27/01	PCT	—	—		
	AL	0	1	7	8	7	3	5	10/25/01	PCT	—	—		
	AM	0	1	7	8	7	4	5	10/25/01	PCT	—	—		
	AN	0	1	8	3	5	1	7	11/08/01	PCT	—	—		
	AO	0	1	8	5	1	3	7	11/15/01	PCT	—	—		
	AP	0	1	8	9	4	9	1	11/29/01	PCT	—	—		
	AQ	0	2	0	3	9	5	8	01/17/02	PCT	—	—		
	AR	0	2	0	7	6	7	2	01/31/02	PCT	—	—		
	AS	0	2	1	1	8	0	3	02/14/02	PCT	—	—		
100	AT	0	2	2	8	3	6	8	04/11/02	PCT	—	—		

EXAMINER

W. W. W. W. W.

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**


FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
10a	AU	0	2	3	0	3	9	4	04/18/02	PCT	—	—		
	AV	0	2	3	4	2	3	7	05/02/02	PCT	—	—		
	AW	0	2	3	8	1	0	7	05/16/02	PCT	—	—		
	AX	0	2	4	3	8	0	6	06/06/02	PCT	—	—		
	AY	0	2	4	5	6	8	2	06/13/02	PCT	—	—		
	AZ	0	2	4	9	6	1	6	06/27/02	PCT	—	—		
	BA	02	0	5	1	4	8	3	07/04/02	PCT	—	—		
	BB	02	0	6	0	5	3	2	08/08/02	PCT	—	—		X*
	BC	02	0	6	0	5	3	3	08/08/02	PCT	—	—		X*
	BD	02	0	6	0	8	7	5	08/08/02	PCT	—	—		
	BE	02	0	6	0	8	9	6	08/08/02	PCT	—	—		
	BF	02	0	6	0	8	9	8	08/08/02	PCT	—	—		
	BG	02	0	6	2	3	1	7	08/15/02	PCT	—	—		
	BH	02	0	8	3	1	1	3	10/24/02	PCT	—	—		
	BI	1	1	5	7	6	8	9	11/28/01	EP (A1)	—	—		
	BJ	1	2	2	9	0	3	4	08/07/02	EP (A1)	—	—		
	BK	1	2	3	6	4	6	7	09/04/02	PCT	—	—		
	BL	19	5	4	1	6	8	9	05/15/96	DE	—	—		X*
	BM	19	8	3	5	3	4	6	02/10/00	DE	—	—		X*
	BN	9	3	1	1	7	7	3	06/24/93	PCT	—	—		
	BO	9	5	0	5	8	0	5	03/02/95	PCT	—	—		
	BP	9	6	1	8	3	8	4	06/20/96	PCT	—	—		
	BQ	9	6	1	9	1	9	8	06/27/96	PCT	—	—		
10b	BR	9	6	1	9	9	6	8	07/04/96	PCT	—	—		

EXAMINER



DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**



FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
kw	BS	9	6	3	2	0	9	5	10/17/96	PCT	—	—		
7	BT	9	8	0	5	3	0	2	02/12/98	PCT	—	—		
	BU	9	8	1	5	2	8	0	04/16/98	PCT	—	—		
	BV	9	8	3	1	3	5	1	07/23/98	PCT	—	—		
	BW	9	8	3	1	3	5	2	07/23/98	PCT	—	—		
	BX	9	8	3	4	5	9	5	08/13/98	PCT	—	—		X*
	BY	9	8	3	4	5	9	6	08/13/98	PCT	—	—		
	BZ	9	8	4	1	1	9	3	09/24/98	PCT	—	—		
	CA	9	9	0	0	1	3	4	01/07/99	PCT	—	—		
	CB	9	9	1	5	1	8	2	04/01/99	PCT	—	—		
	CC	9	9	3	0	7	0	3	06/24/99	PCT	—	—		
	CD	9	9	4	0	9	3	9	08/19/99	PCT	—	—		
	CE	9	9	4	8	4	7	6	09/30/99	PCT	—	—		
kw	CF	9	9	6	1	0	0	3	12/02/99	PCT	—	—		

X\* = English Language Derwent Abstract is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

kw	CG	Barnes, P.J., "Scientific rationale for inhaled combination therapy with long-acting $\beta_2$ -agonists and corticosteroids," <i>Eur. Respir. J.</i> <u>19</u> : 182-191 (2002)
7	CH	Campestrini <i>et al.</i> , "Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection," <i>Journal of Chromatography B</i> <u>704</u> : 221-229 (1997)
	CI	Cazzola <i>et al.</i> , "Long-Acting $\beta_2$ -Agonists in the Treatment of Acute Exacerbations of COPD," <i>Clin. Drug Invest.</i> <u>22(6)</u> : 369-376 (2002)
kw	CJ	Derwent#010743444, WPI Acc No.:1996-240399/199625 for German Patent Application DE 19541689, "Medicament contg. ciclesonid and beta2-sympathomimetic - for treating chronic obstructive respiratory disease,"

EXAMINER

kw. *Wlodarczyk*

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

26	CK	Derwent#012030009, WPI Acc No.:1998-446919-199838 for PCT Patent Application WO 98/34595, "Pressurised liquid aerosol propellant for pharmaceutical inhalers-contains carbon dioxide and hydro-fluoroalkane; gives more consistent dosing and a better particle size spectrum,"
	CL	Derwent#013011051, WPI Acc No.:2000-182903/200016 for PCT Patent Application WO 00/06121, "Aerosol propellant comprising dinitrogen monoxide and hydrofluoroalkane and optionally containing a pharmaceutically active substance,"
	CM	Derwent#013023586, WPI Acc No. 2000-195437/200017, for PCT Patent Application WO 00/07567 "Aerosol formulation for drug administration, containing small amount of cromoglycate or nedocromil salt as drug carrier, to improve dispersion stability and accuracy of dosing,"
	CN	Derwent#013024375, WPI Acc No.: 2000-196226/200018 for German Patent Application DE 19835346, "Two-part drug capsule for use in powder inhalers is formed from hydrophobic plastics, preferably high density polyethylene,"
	CO	Derwent#013227765, WPI Acc No. 2000-399639/200034, for PCT Patent Application, WO 00/28979 "Use of magnesium stearate for stabilization of dry powder inhalation formulations to improve resistance to moisture,"
	CP	Derwent#013790372, WPI Acc No.: 2001-274583/200129, for PCT Patent Application, WO 01/22956 "Drug combination of soft steroid and beta-2-adrenoceptor agonist, administered by inhalation for effective treatment of respiratory or allergic diseases, e.g. asthma,"
	CQ	Derwent#014808338, WPI Acc No.:2002-629044/200268, for PCT Patent Application, WO 02/060533 "Medicament containing a betamimetic and an oxitropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	CR	Derwent#014816787, WPI. Acc No.: 2002-637493/200269, for PCT Patent Application, WO 02/060532 "Medicament containing a betamimetic and an ipratropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	CS	Eickelberg <i>et al.</i> , "Ligand-independent Activation of the Glucocorticoid Receptor by $\beta_2$ -Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and vascular Smooth Muscle Cells," <i>The Journal of Biological Chemistry</i> <u>274</u> (2): 1005-1010 (1999)
	CT	Farmer <i>et al.</i> , "6-Adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the I $\kappa$ B/NF- $\kappa$ B pathway," <i>Am. J. Physiol. Lung. Cell. Mol. Physiol.</i> <u>279</u> : 1675-682 (2000)
20	CU	Greening <i>et al.</i> , "Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid," <i>The Lancet</i> <u>344</u> : 219-224 (1994)

EXAMINER

40. Whidden

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	CV	Grootendorst <i>et al.</i> , "Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma," <i>Eur. Respir. J.</i> <u>17</u> : 374-379 (2001)
	CW	Ida, Hisashi, "Pharmacology of Formoterol, ( $\alpha$ RS)-3-formamido-4-hydroxy- $\alpha$ -[[[( $\alpha$ RS)- <i>p</i> -methoxy- $\alpha$ -methylphenethyl] amino] methyl] benzylalcohol fumarate dihydrate (BD 40A)," <i>Oyo Yakuri</i> <u>21(2)</u> : 201-210 (1981)
	CX	Ito <i>et al.</i> , "Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-16-Induced Histone H4 Acetylation on Lysines 8 and 12," <i>Molecular and Cellular Biology</i> <u>20(18)</u> : 6892-6903 (2000)
	CY	Ito <i>et al.</i> , "p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids," <i>The Journal of Biological Chemistry</i> <u>276(32)</u> : 30208-30215 (2001)
	CZ	Korn <i>et al.</i> , "Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells," <i>Eur. Respir. J.</i> <u>17</u> : 1070-1077 (2001)
✓	DA	Lipworth <i>et al.</i> , "Effects of Treatment with Formoterol on Bronchoprotection against Methacholine," <i>Am. J. Med.</i> <u>104</u> : 431-438 (1998)
	DB	Malolepszy <i>et al.</i> , "Safety of formoterol Turbuhaler™ at cumulative dose of 90 $\mu$ g in patients with acute bronchial obstruction," <i>Eur. Respir. J.</i> <u>18</u> : 928-934 (2001)
	DC	O'Connor, B.J., "Combination Therapy," <i>Pulmonary Pharmacology &amp; Therapeutics</i> <u>11</u> : 397-399 (1998)
	DD	Oddera <i>et al.</i> , "Salmeterol Enhances the Inhibitory Activity of Dexamethasone on Allergen-Induced Blood Mononuclear Cell Activation," <i>Respiration</i> <u>65</u> : 199-204 (1998)
	DE	Package Insert for: ADVAIR™ DISKUS <a href="http://fb.a-files.net/PackageInsert/Advair.htm">http://fb.a-files.net/PackageInsert/Advair.htm</a> (accessed on 09/26/02) (Copyright, 1999 Glaxo Wellcome Inc.)
	DF	Palmqvist <i>et al.</i> , "Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers," <i>Pulmonary Pharmacology &amp; Therapeutics</i> <u>14</u> : 29-34 (2001)
	DG	Pang, L. and A.J. Knox, "Regulation of TNF- $\alpha$ -induced eotaxin release from cultured human airway smooth muscle cells by $\beta_2$ -agonists and corticosteroids," <i>FASEB J.</i> <u>15</u> : 261-269 (2001)
	DH	Pang, L. and A.J. Knox, "Synergistic Inhibition by $\beta_2$ -Agonists and Corticosteroids on Tumor Necrosis Factor- $\alpha$ -Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells," <i>Am. J. Respir. Cell Mol. Biol.</i> <u>23</u> : 79-85 (2000)
RW	DI	Pauwels <i>et al.</i> , "Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma," <i>The New England Journal of Medicine</i> <u>337(20)</u> : 1405-1411 (1997)

EXAMINER

W. Widdows

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1013	SERIAL NO. 09/887,281
	APPLICANT Banerjee <i>et al.</i>	
	FILING DATE June 22, 2001	GROUP 1614

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

W	DJ	Schreurs <i>et al.</i> , "A dose-response study with formoterol Turbuhaler™ as maintenance therapy in asthmatic patients," <i>Eur. Respir. J.</i> <u>9</u> : 1679-1683 (1996)
	DK	Seldon <i>et al.</i> , "Albuterol Does Not Antagonize the Inhibitory Effect of Dexamethasone on Monocyte Cytokine Release," <i>Am. J. Respir. Crit. Care Med.</i> <u>157</u> : 803-809 (1998)
	DL	Silvestri <i>et al.</i> , "Fluticasone and salmeterol downregulate <i>in vitro</i> , fibroblast proliferation and ICAM-1 or H-CAM expression," <i>Eur. Respir. J.</i> <u>18</u> : 139-145 (2001)
	DM	Sköld <i>et al.</i> , "Glucocorticoids Augment Fibroblast-Mediated Contraction of Collagen Gels by Inhibition of Endogenous PGE Production," <i>Proceedings of the Association of American Physicians</i> <u>111(3)</u> : 249-258 (1999)
	DN	Stewart <i>et al.</i> , "Acute formoterol administration has no argogenic effect in nonasthmatic athletes," <i>Medicine &amp; Science In Sports &amp; Exercise</i> <u>34(2)</u> : 213-217 (2002)
	DO	Vianna, E.O. and R.J. Martin, "Bronchodilators and Corticosteroids in the Treatment of Asthma," <i>Drugs of Today</i> <u>34(3)</u> : 203-223 (1998)
	DP	Wilding <i>et al.</i> , "Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study," <i>British Medical Journal</i> <u>314</u> : 1441-1446 (1997)
W	DQ	Woolcock <i>et al.</i> , "Comparison of Addition of Salmeterol to Inhaled Steroids with Doubling of the Dose of Inhaled Steroids," <i>Am.J. Respir. Crit. Care Med.</i> <u>153</u> : 1481-1488 (1996)

EXAMINER

W. Widdows

DATE CONSIDERED

1-17-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **BRONCHODILATING COMPOSITIONS AND METHODS**